Open AccessAre We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB
Author(s) -
Elisa H. Ignatius,
Susan Swindells
Publication year - 2020
Publication title -
current hiv/aids reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.135
H-Index - 56
eISSN - 1548-3576
pISSN - 1548-3568
DOI - 10.1007/s11904-020-00529-8
Subject(s) - medicine , tuberculosis , short course , latent tuberculosis , antiretroviral therapy , intensive care medicine , human immunodeficiency virus (hiv) , disease , directly observed therapy , drug , incidence (geometry) , immunology , mycobacterium tuberculosis , pediatrics , pharmacology , viral load , pathology , physics , optics
Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom